IHEEZO
Peakchloroprocaine hydrochloride ophthalmic gel
NDAOPHTHALMICGEL
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
IHEEZO (chloroprocaine hydrochloride ophthalmic gel) is 12. First approved in 2022.
Drug data last refreshed 16h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IHEEZO is a topical ophthalmic gel formulation of chloroprocaine hydrochloride, a local anesthetic that blocks nerve impulse generation and conduction in ocular tissues. It is indicated for rapid onset topical anesthesia in the eye, working by increasing the electrical excitation threshold in nerve fibers. The drug enables pain relief and sensory loss progression (pain → temperature → touch → proprioception → muscle tone) for ophthalmic procedures.
Peak12.6 years to LOE
Product is in peak commercial phase with no reported Part D spending data; team likely focused on market penetration and sustained adoption in ophthalmic practices.
Mechanism of Action
12.1 Mechanism of Action 12.1 Mechanism of Action Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.